ClinicalTrials.gg
RecruitingNCT07009652Updated Jun 6, 2025

Optimization of Transport and Use of a Mobile ECMO Team in Patients With Sudden Cardiac Arrest in the Moravian-Silesian Region

An observational study in Cardiac Arrest With Successful Resuscitation and Cardiac Arrest, Cause Unspecified, sponsored by University Hospital Ostrava. Recruiting at 2 sites in Czechia. Open to participants aged 3 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by University Hospital Ostrava · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
3 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Heart Arrest with a site in Czechia — 7 open to participants now, 8 under way, none of them phase 3. Heart Arrest · Czechia.

Started
2025
with 2 others
Observational
7 of 15
3 open now
Registered
10th of 15
by date
Lead sponsor
5 of 15
University Hospital Ostrava

Among the 15 studies in Heart Arrest with a site in Czechia, this one is one of 3 that started in 2025, is one of 7 observational ones, and was the 10th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

7 of the 15 studies in Heart Arrest with a site in Czechia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 3 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Heart Arrest with a site in Czechia, or all of them as a file.
02

Study summary

This study evaluates the feasibility of implementing a mobile extracorporeal membrane oxygenation (ECMO) team and optimizing patient transport logistics.

Read the detailed description

The aim of the study is to improve neurological outcomes in out-of-hospital cardiac arrest (OHCA) cases in the Moravian-Silesian Region. By analysing regional epidemiological and demographic data, the project aims to identify key factors for reducing the time from collapse to the initiation of ECMO and to support the development of effective protocols for extracorporeal cardiopulmonary resuscitation (ECPR).

03

Conditions studied

  • Cardiac Arrest With Successful Resuscitation
  • Cardiac Arrest, Cause Unspecified

Keywords

  • cardiac arrest
  • extracorporeal membrane oxygenation
  • out-of-hospital cardiac arrest
  • extracorporeal cardiopulmonary resuscitation
04

Who can participate

Ages eligible
3 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients indicated for ECPR after out-of-hospital cardiac arrest, for whom transport of the patient to an ECMO centre or deployment of an ECMO team is logistically manage-able.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • out-of-hospital cardiac arrest
  • indication for ECPR

Exclusion criteria

Exclusion Criteria:

  • death at the scene of the accident
  • withdrawal of the
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • ECPR and ECMO

    Patients undergoing extracorporeal cardiopulmonary resuscitation (ECPR).

    Procedure: Extracorporeal cardiopulmonary resuscitation (ECPR)

Interventions

  • ProcedureExtracorporeal cardiopulmonary resuscitation (ECPR)

    Extracorporeal cardiopulmonary resuscitation (commonly known as ECPR) is a method of cardiopulmonary resuscitation (CPR) that passes the patient's blood through a machine in a process to oxygenate the blood supply.

06

What researchers measure

Primary outcomes

  1. Neurological outcome after 30 days (CPC score)

    Assessment of the neurological status of patients 30 days after the event using the Cerebral Performance Category (CPC) scale, which measures the extent of neurological impairment: * CPC 1 = good neurological condition * CPC 2 = mild impairment * CPC 3-5 = serious impairment, vegetative state or death The primary endpoint of the study is the proportion of patients with a favourable neurological outcome (CPC 1-2).

    Time frame: 30 days

Secondary outcomes

  1. Time from collapse to initiation of ECMO

    Measuring the time (in minutes) from patient collapse to ECMO initiation. The aim is to analyse how this time affects neurological outcome.

    Time frame: Up to 2 hours

  2. Transport time to the ECMO centre

    Measurement of the time (in minutes) from the arrival of the Emergency Medical Services (EMS) at the scene to the admission of the patient to the ECMO centre.

    Time frame: Up to 2 hours

  3. Arrival time for the mobile ECMO team to the scene

    Time interval (in minutes) from activation of the mobile ECMO team to its arrival at the scene. The aim is to evaluate the effectiveness of the model and the potential time benefit of intervention in the field.

    Time frame: Up to 2 hours

07

Study locations

2 of 2 sites recruiting
  • Emergency Medial Services, Moravian-Silesian Region
    Ostrava, Moravian-Silesian Region 70030, Czechia
    Recruiting
    • Filip Burša, MD, Ph.D., EDEC · Contactfilip.bursa@fno.cz · 0042059737
    • Filip Burša, MD, Ph.D., EDEC · Principal investigator
  • University Hospital Ostrava
    Ostrava, Moravian-Silesian Region 70852, Czechia
    Recruiting
    • Jiří Hynčica · Contactjiri.hyncica@fno.cz · 0042059737
    • Nela Walachová, Mgr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make individual participant data available to other researchers. The data may be provided upon request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2026, 12 months after the start.

Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 12 months is below that.

Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
Jun 6, 2025
StartActual
May 1, 2025
Primary completionEst.
May 1, 2026
CompletionEst.
May 1, 2028
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07009652
Collaborators
Emergency Medical Services, Moravian-Silesian Region
Responsible party
Sponsor
First posted
Jun 6, 2025
Start date
May 1, 2025
Primary completion
May 1, 2026 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Jun 6, 2025

Study contacts

Jiří Hynčica
Contact
jiri.hyncica@fno.cz
0042059737 ext. 2587
Nela Walachová, Mgr.
principal investigator · University Hospital Ostravs

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion